Literature DB >> 27459986

Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors.

Jonathan C King1,2, Mazen Zenati1, Jennifer Steve1, Sharon B Winters3, David L Bartlett1, Amer H Zureikat1, Herbert J Zeh1, Melissa E Hogg4.   

Abstract

BACKGROUND: Morbidity and mortality of pancreatectomy has improved and chemotherapeutic options for pancreatic cancer (PC) are growing, yet there is reluctance to treat octogenarians. This study examined the reasons for failure to treat and analyzes outcomes in octogenarians with PC.
METHODS: Retrospective chart review 2005-2013. Demographics, tumor characteristics, treatment, reason for lack of treatment, Charlson comorbidity index (CCI), and survival were analyzed. Expected treatment for early-stage patients (I/II) included surgery ± chemotherapy ± radiation. Expected treatment for advanced stage patients (III/IV) was chemotherapy.
RESULTS: A total of 431 octogenarians were analyzed. Mean age was 84.0 ± 3.4, 59.6 % female, and 44.1 % received no treatment. Patients with operable tumors (I = 31 [7.2 %]/II = 214 [49.7 %]) had surgery 39.2 % of the time. Age was a predictor of not receiving surgery (odds ratio [OR] 0.78; 95 % confidence interval [CI] 0.70-0.86; p = 0.0001), whereas CCI was not. The most common reason for no surgery was contraindication despite similar CCI. Median overall survival for early-stage patients was better in the surgical group (15.8 vs. 5.5 months) than nonsurgical group (p < 0.0001). Advanced patients (III = 54 [12.5 %]/IV = 132 [30.6 %]) had similarly low treatment rates (n = 65 [34.9 %]). Survival for advanced disease was best for treated patients (6.9 vs. 1.8 months; p < 0.0001). CCI did not differ between those receiving chemotherapy and not, although age was significantly different (p < 0.0001).
CONCLUSIONS: There is significant deviation from expected treatment for octogenarians with PC. While no correlation existed between CCI and treatment, age correlated with therapy for nearly all stages. Chronological age, not comorbidity, may drive recommendation for treatment in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27459986     DOI: 10.1245/s10434-016-5456-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.

Authors:  Penny Fang; Weiguo He; Daniel R Gomez; Karen E Hoffman; Benjamin D Smith; Sharon H Giordano; Reshma Jagsi; Grace L Smith
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-01       Impact factor: 7.038

2.  Minimally invasive distal pancreatectomy: greatest benefit for the frail.

Authors:  Ioannis T Konstantinidis; Aaron Lewis; Byrne Lee; Susanne G Warner; Yanghee Woo; Gagandeep Singh; Yuman Fong; Laleh G Melstrom
Journal:  Surg Endosc       Date:  2017-05-10       Impact factor: 4.584

Review 3.  Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.

Authors:  Gwenalyn Garcia; Marcel Odaimi
Journal:  J Gastrointest Cancer       Date:  2017-06

4.  Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.

Authors:  Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

5.  Survival outcomes of surgical and non-surgical treatment in elderly patients with stage I pancreatic cancer: A population-based analysis.

Authors:  Duorui Nie; Qingxia Lan; Bin Shi; Fei Xu
Journal:  Front Med (Lausanne)       Date:  2022-09-29

6.  Long-Term Survival and Risk of Institutionalization in Onco-Geriatric Surgical Patients: Long-Term Results of the PREOP Study.

Authors:  Monique G Huisman; Federico Ghignone; Giampaolo Ugolini; Grigory Sidorenkov; Isacco Montroni; Antonio Vigano; Nicola de Liguori Carino; Eriberto Farinella; Roberto Cirocchi; Riccardo A Audisio; Geertruida H de Bock; Barbara L van Leeuwen
Journal:  J Am Geriatr Soc       Date:  2020-03-10       Impact factor: 5.562

7.  Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study.

Authors:  Lydia G M van der Geest; Casper H J van Eijck; Bas Groot Koerkamp; Valery E P P Lemmens; Olivier R Busch; Pauline A J Vissers; Johanna W Wilmink; Marc G Besselink
Journal:  Cancer Med       Date:  2018-09-06       Impact factor: 4.452

8.  Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer.

Authors:  Hyeong Min Park; Sang-Jae Park; Sung-Sik Han; Seoung Hoon Kim
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

9.  First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017.

Authors:  Mee Joo Kang; Jiwon Lim; Sung-Sik Han; Hyeong Min Park; Sang-Jae Park; Young-Joo Won; Sun-Whe Kim
Journal:  Cancer Res Treat       Date:  2021-05-21       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.